Actively Recruiting
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Led by Peking Union Medical College · Updated on 2026-04-02
39
Participants Needed
2
Research Sites
255 weeks
Total Duration
On this page
Sponsors
P
Peking Union Medical College
Lead Sponsor
P
Peking University Hospital of Stomatology
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.
CONDITIONS
Official Title
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histopathologic diagnosis of salivary gland carcinoma
- Tumor tissues tested with HER2, NTRK, AR, or TROP-2 immunohistochemical staining
- ECOG physical status score of 0 or 1 within 3 days before starting treatment
- Age 18 years or older, no upper age limit
- Life expectancy greater than 3 months
- At least one measurable lesion by RECIST 1.1 criteria
- Women of childbearing potential must have a negative pregnancy test within 7 days before treatment and agree to use contraception
- Adequate liver, kidney, bone marrow, heart, lung, and other organ functions
- Ability to understand and voluntarily sign informed consent
- Ability to comply with study visit schedules and requirements
You will not qualify if you...
- Known allergy or delayed severe reaction to any study drugs
- Major surgery within 4 weeks before study start without full recovery
- Receipt of live vaccine within 4 weeks before study start or planned vaccination during study
- History of arterial or venous thrombosis within 6 months before medication
- Major cardiovascular diseases
- Uncontrolled systemic diseases such as diabetes, hypertension, pulmonary fibrosis, acute lung disease, interstitial lung disease, or cirrhosis
- Active infection requiring systemic treatment
- History of active tuberculosis
- Positive HIV test
- Chronic hepatitis B or active hepatitis C
- Conditions that may affect safety or study compliance as judged by investigators
- Pregnancy, breastfeeding, or intention to become pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Fei Ma
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
2
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
Actively Recruiting
Research Team
F
fei Ma
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
20
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here